Organizing services for cardiovascular prevention

Opinion statementWith an aging population, cardiovascular disease (CVD) prevalence will continue to increase for at least the next 30 years. Current clinical trial evidence expands the indications for aggressive treatment of risk factors. Concurrently, the use of new screening and diagnostic technologies will expand the number of identified high-risk individuals requiring clinical care. These likely scenarios will force efficient resource allocation. The impression of the authors is that new models of shared responsibilities of care are needed to enable CVD prevention. All stages of care for those with CVD should entail cooperation among nurses, pharmacists, primary care providers, and cardiovascular specialists in delivering comprehensive, evidence-based care. The persistent treatment gap between current knowledge and clinical practice suggests old models of acute patient care by specialists require revision into fundamentally different systems of long-term care by a team of providers such as that proposed by the Chronic Care Model.

[1]  G. Balady,et al.  Transforming exercise-based cardiac rehabilitation programs into secondary prevention centers: a national imperative. , 2001, Journal of cardiopulmonary rehabilitation.

[2]  I. Ockene,et al.  Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. , 1997, Circulation.

[3]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[4]  James A. Blumenthal,et al.  Cardiac rehabilitation as secondary prevention , 1995 .

[5]  Thomas Bodenheimer,et al.  Improving primary care for patients with chronic illness. , 2002, JAMA.

[6]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.

[7]  Kevin Weiss,et al.  The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus , 2003, Annals of Internal Medicine.

[8]  R. Greenberg Overview of patient compliance with medication dosing: a literature review. , 1984, Clinical therapeutics.

[9]  Sarah Corley,et al.  A Multimethod Quality Improvement Intervention To Improve Preventive Cardiovascular Care , 2004, Annals of Internal Medicine.

[10]  S. Grundy,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive Summary Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association , 2002, Circulation.

[11]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.

[12]  Rowena J Dolor,et al.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Journal of the American College of Cardiology.

[13]  T. Pearson,et al.  Screening family members at high risk for coronary disease. Why isn't it done? , 2001, American journal of preventive medicine.

[14]  D. Berry,et al.  Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. , 2003, Archives of internal medicine.

[15]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[16]  S. Ornstein,et al.  Quality improvement using electronic medical records: a case study of a high-performing practice. , 2001, Topics in health information management.

[17]  J. Blumenthal,et al.  Cardiac rehabilitation as secondary prevention. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. , 1995, Clinical practice guideline. Quick reference guide for clinicians.

[18]  R. Krauss,et al.  Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.

[19]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[20]  C. Lenfant Conquering cardiovascular disease: progress and promise. , 1999, JAMA.

[21]  M Hørder,et al.  Randomised controlled trial of structured personal care of type 2 diabetes mellitus , 2001, BMJ : British Medical Journal.

[22]  R. Haynes,et al.  Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review. , 1998, JAMA.

[23]  V. Fuster,et al.  Task force #5--the role of cardiovascular specialists as leaders in prevention: from training to champion. 33rd Bethesda Conference. , 2002, Journal of the American College of Cardiology.

[24]  G. Balady,et al.  Comparison of outcome of cardiac rehabilitation in black women and white women. , 1995, The American journal of cardiology.

[25]  J. Mckenney,et al.  Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. , 2005, The American journal of cardiology.

[26]  S. Smith Clinical treatment of dyslipidemia: practice patterns and missed opportunities. , 2000, The American journal of cardiology.

[27]  S. Connolly,et al.  Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. , 1999, Psychosomatic medicine.

[28]  C. McDonald Protocol-based computer reminders, the quality of care and the non-perfectability of man. , 1976, The New England journal of medicine.

[29]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[30]  James C. Robinson,et al.  External incentives, information technology, and organized processes to improve health care quality for patients with chronic diseases. , 2003, JAMA.

[31]  D. B. Friedman,et al.  Compliance and efficacy of cardiac rehabilitation and risk factor modification in the medically indigent. , 1997, The American journal of cardiology.

[32]  J. Fleg,et al.  Secondary Prevention of Coronary Heart Disease in the Elderly (With Emphasis on Patients ≥75 Years of Age): An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention , 2002, Circulation.

[33]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[34]  S. Grundy,et al.  Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[35]  T. Robinson,et al.  Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. , 2005, Circulation.

[36]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[37]  Thomas Bodenheimer,et al.  Improving primary care for patients with chronic illness: the chronic care model, Part 2. , 2002, JAMA.

[38]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[39]  J S Berg,et al.  Medication compliance: a healthcare problem. , 1993, The Annals of pharmacotherapy.

[40]  Sankey V. Williams,et al.  Evaluation of Primary Care Patients with Chronic Stable Angina: Guidelines from the American College of Physicians , 2004, Annals of Internal Medicine.

[41]  T. Pearson Primer in Preventive Cardiology , 1994 .

[42]  E. Benjamin,et al.  Discovering the Full Spectrum of Cardiovascular Disease: Minority Health Summit 2003: Report of the Outcomes Writing Group , 2005, Circulation.

[43]  M. Smith,et al.  Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002 .

[44]  J. Sallis,et al.  American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. , 2003, Circulation.

[45]  D. Sackett,et al.  Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. , 1977, Clinical pharmacology and therapeutics.

[46]  C. Viscoli,et al.  Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.

[47]  Brian T. Austin,et al.  Organizing care for patients with chronic illness. , 1996, The Milbank quarterly.

[48]  John Horgan,et al.  Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. , 2004, Circulation.

[49]  Sandeep Vijan,et al.  Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians , 2004, Annals of Internal Medicine.

[50]  D. Atkins,et al.  American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. , 2003, Circulation.

[51]  T. Fahey,et al.  Interventions to improve adherence to lipid-lowering medication. , 2016, The Cochrane database of systematic reviews.

[52]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[53]  C. Feifer,et al.  System supports for chronic illness care and their relationship to clinical outcomes. , 2001, Topics in health information management.

[54]  D. Bates,et al.  Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. , 2003, Archives of internal medicine.

[55]  R B Haynes,et al.  Interventions to enhance medication adherence. , 2005, The Cochrane database of systematic reviews.

[56]  R. Gliklich,et al.  Get With the Guidelines for Cardiovascular Secondary Prevention , 2004 .

[57]  D. Salem,et al.  Prevalence of risk factors in men with premature coronary artery disease. , 1991, The American journal of cardiology.

[58]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.